



April 30, 2014

## Prothena Announces Appointment of Chief Legal Officer

DUBLIN, Ireland, April 30, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the appointment of Arthur W. ("Bill") Homan as Chief Legal Officer.

"Bill has broad legal experience with publicly-traded, development and commercial-stage life science companies," said Dr. Dale Schenk, President and Chief Executive Officer of Prothena. "In particular, his background in managing corporate governance and compliance programs, supporting operational teams, and advising on various business transactions will strengthen our management team as we continue to target proteins in novel ways to resolve unmet clinical needs in patients."

Prior to joining Prothena, Mr. Homan was Senior Vice President, General Counsel and Secretary at Complete Genomics, Inc., a life sciences company, until its sale in 2013. Previously, Mr. Homan was Senior Vice President, General Counsel and Secretary of Varian, Inc., a life science instruments company, from 1999 until its acquisition in 2010 by Agilent Technologies, Inc. Prior to that, he served at Varian Associates, Inc. as Associate General Counsel, and at a San Francisco law firm. Mr. Homan received a B.A. in Economics and Political Science from Virginia Polytechnic Institute and State University, and a J.D. from the University of Virginia.

### About Prothena

Prothena Corporation plc is a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. These potential therapies have a number of indications, including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in inflammatory diseases and metastatic cancers (PRX003). For more information, please visit [www.prothena.com](http://www.prothena.com).

### Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to, among other things, our expectations regarding our Chief Legal Officer's contributions to Prothena. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "plan," "predict," "project," "potential," "target," "will" and similar terms and phrases, including references to assumptions. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors including, but not limited to the risks and uncertainties described in the "Risk Factors" section of Prothena's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 7, 2014, and the "Risk Factors" section of our and Quarterly Reports on Form 10-Q filed with the SEC from time to time. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in Prothena's expectations.

CONTACT: Investors: Tran Nguyen, CFO

650-837-8535, IR@prothena.com

Media: Anita Kawatra

646-256-5116, anita.kawatra@prothena.com